Akira Yamamiya, Katsuya Kitamura, Yu Ishii, Yuta Mitsui, Hitoshi Yoshida
{"title":"Safety of endoscopic sphincterotomy in patients undergoing antithrombotic treatment: a retrospective study.","authors":"Akira Yamamiya, Katsuya Kitamura, Yu Ishii, Yuta Mitsui, Hitoshi Yoshida","doi":"10.1177/2631774519846327","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study investigated the safety of endoscopic sphincterotomy in patients undergoing antithrombotic treatment.</p><p><strong>Methods: </strong>From January 2014 to December 2016, a single-center retrospective study was conducted. Of the 80 patients with naïve papilla receiving antithrombotic treatment who underwent endoscopic sphincterotomy, 76 patients were retrospectively analyzed. We divided the participants into two groups as follows: 45 patients who discontinued antithrombotic treatment (discontinuation group) and 31 patients who continued antithrombotic treatment (continuation group). We evaluated the safety of endoscopic sphincterotomy in patients with naïve papilla who received antithrombotic treatment.</p><p><strong>Results: </strong>The percentage of patients requiring emergency endoscopic retrograde cholangiopancreatography in the continuation group was significantly higher than that in the discontinuation group (55% vs 11%; <i>p</i> = 0.001). The incidence of adverse events did not differ significantly between the two groups. Neither bleeding nor perforation occurred in either group. The length of hospital stay did not differ significantly between the two groups.</p><p><strong>Conclusions: </strong>Endoscopic sphincterotomy in patients undergoing antithrombotic treatment may be safe if the guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment are followed.</p>","PeriodicalId":40947,"journal":{"name":"Therapeutic Advances in Gastrointestinal Endoscopy","volume":"12 ","pages":"2631774519846327"},"PeriodicalIF":3.0000,"publicationDate":"2019-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2631774519846327","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastrointestinal Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2631774519846327","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 7
Abstract
Background: This study investigated the safety of endoscopic sphincterotomy in patients undergoing antithrombotic treatment.
Methods: From January 2014 to December 2016, a single-center retrospective study was conducted. Of the 80 patients with naïve papilla receiving antithrombotic treatment who underwent endoscopic sphincterotomy, 76 patients were retrospectively analyzed. We divided the participants into two groups as follows: 45 patients who discontinued antithrombotic treatment (discontinuation group) and 31 patients who continued antithrombotic treatment (continuation group). We evaluated the safety of endoscopic sphincterotomy in patients with naïve papilla who received antithrombotic treatment.
Results: The percentage of patients requiring emergency endoscopic retrograde cholangiopancreatography in the continuation group was significantly higher than that in the discontinuation group (55% vs 11%; p = 0.001). The incidence of adverse events did not differ significantly between the two groups. Neither bleeding nor perforation occurred in either group. The length of hospital stay did not differ significantly between the two groups.
Conclusions: Endoscopic sphincterotomy in patients undergoing antithrombotic treatment may be safe if the guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment are followed.
背景:本研究探讨了内镜下括约肌切开术在接受抗血栓治疗的患者中的安全性。方法:2014年1月至2016年12月进行单中心回顾性研究。在接受抗血栓治疗的80例naïve乳头患者中,有76例患者接受了内窥镜括约肌切开术。我们将参与者分为两组:45名停止抗血栓治疗的患者(停药组)和31名继续抗血栓治疗的患者(继续组)。我们评估了内窥镜下括约肌切开术对接受抗血栓治疗的naïve乳头患者的安全性。结果:继续组需要急诊内镜逆行胆管造影的患者比例显著高于停药组(55% vs 11%;p = 0.001)。两组不良事件发生率无显著差异。两组均未发生出血和穿孔。两组患者住院时间无显著差异。结论:如果在接受抗血栓治疗的患者中遵循胃肠内镜指南,内镜下括约肌切开术可能是安全的。